Preventing peanut allergy thanks to the microbiota?

Could a gut microbiota imbalance be involved in the development of peanut allergy? This is the hypothesis of a study conducted over nearly a decade and published in the prestigious journal JACI.

The gut microbiota Food allergies

For children, peanut allergy is a common but serious challenge. In Western countries, it affects almost 2% of children. 1 Symptoms include breathing difficulties, swelling of the throat, diarrhea, nausea, skin rashes, and fainting. These symptoms vary in severity, but the most serious, anaphylaxis – an intense whole-body reaction – can prove fatal. 2,3 Peanut allergy often manifests itself in early childhood, can be much more severe than other food allergies, and, unlike them, lasts into adulthood in 80% of cases. 1

2% In Western countries, peanut allergy affects almost 2% of children.

80% Peanut allergy can be much more severe than other food allergies and lasts into adulthood in 80% of cases.

A link between the microbiota and food allergy?

What about the gut microbiota? For many years, it has been known that the microbial communities in the gut also play a key role in building the immune system. Recent research even suggests that the gut microbiota may be involved in the development of food allergies. Patients with food allergies present an unbalanced gut microbiota.

So, what happens in early childhood before allergies even appear? Researchers in the US set out to answer this question by analyzing the microbiota of 122 children from infancy to the onset of the allergy. Their aim was to better understand how the allergy develops, with the hope of one day being able to prevent it.

The immune system

The first years of a child’s life are crucial, since during this period the immune system develops intensively, greatly influencing its ability to fight infections and allergies later in life.

Tell me about your microbiota, and I’ll tell you your future allergy...

The researchers’ first finding was that patients who developed peanut allergy around the age of nine had a poorly diversified gut microbiota during their first months of life. Their microbial communities evolved more dynamically, with a less homogeneous distribution of species compared to the microbiota of children who did not develop the allergy, while their gut flora evolved more continuously and homogeneously over time.

Are cow’s milk allergy and gut microbiota related?

Learn more

Their second finding was that certain species of the Clostridium genus were more present in infants who did not have peanut allergy, while Streptococcus sp were more present in those who did. By the age of nine, Bifidobacterium, well-known beneficial bacteria, were more present in non-allergic patients.

In addition to the changes in abundance of certain bacteria being different between the two groups of children, the authors observed that the metabolites produced by the microbiota, i.e., the metabolome, were different in the children who developed an allergy. In particular, certain  (sidenote: Short chain fatty acids (SCFA) Short chain fatty acids (SCFA) are a source of energy (fuel) for an individual’s cells. They interact with the immune system and are involved in communication between the intestine and the brain. Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Front Endocrinol (Lausanne). 2020;11:25. ) , such as butyrate and isovalerate, decreased over time in the children who subsequently developed an allergy. Isovalerate is already known for its protective properties against allergy (asthma and atopy).

The development of peanut allergy was associated with changes in 139 metabolites, and particularly with a pathway for the metabolism of histidine, the precursor of histamine, a bioactive molecule released during allergic reactions.

Towards the early prevention of peanut allergy?

The authors hypothesize that the development of the allergy may be linked to a less diverse microbiota in infants, associated with changes in the abundance of specific bacteria at a key age of immune system development. This information gives us a better understanding of the mechanism behind the development of peanut allergy and may lead to microbiota-based therapies to prevent it.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News

Predicting the risk of preterm birth through vaginal microbiota

During pregnancy, the genetic structure of the bacterial population in the vaginal microbiota seems to follow a specific trajectory when gestation leads to preterm birth. Gardnerella spp. is believed to be a signature of preterm birth.

Respiratory, gastrointestinal and neurodevelopmental complications: (sidenote: Preterm birth birth before 37 completed weeks of gestation. There are sub-categories of preterm birth, based on gestational age:
- extremely preterm (less than 28 weeks);
- very preterm (between 28 and 32 weeks);
- moderate to late preterm (between 32 and 37 weeks). Source: WHO
)
is the main cause of neonatal morbidity and mortality. The vaginal microbiota seems to be involved, but the underlying mechanisms remain poorly understood. This flora can change rapidly during gestation, due to hormonal changes, genital infections, antibiotics, etc. A team of researchers and clinicians from the states of New York and Virginia tracked the genome of the vaginal microbiota of 175 American women throughout their pregnancies (40 of whom subsequently experienced spontaneous preterm delivery, and 135 of whom delivered at full term).

27% Only 27% of women surveyed say they know that the vaginal microbiota is balanced when its bacterial diversity is low

Higher genetic diversity

The study shows that the two types of pregnancy differ in terms of vaginal microbiota composition: certain bacterial species of the Lactobacillus genus, such as L. helveticus, L. crispatus, L. gasseri and L. jensenii, are associated with full-term pregnancies, while Megasphaera genomosp, Gardnerella spp. and Atopobium vaginae are linked to preterm births.
Another finding is that the genetic diversity of the vaginal microbiota is higher in the first half of pregnancies that end preterm, due to Gardnerella species. More precisely, the (sidenote: Nucleotide diversity number of nucleotide differences for a given sequence for 2 individuals (here 2 bacteria) randomly selected in the population. ) of Gardnerella spp. increases at the start of pregnancies that end preterm - peaking at around 13 weeks of gestation, then returning to its initial value at around 20 weeks of gestation - whereas it remains stable in pregnancies that are carried to term. The genetic diversity of Gardnerella spp. during the first half of pregnancy therefore appears to affect pregnancy outcomes and could perhaps be used as a biomarker for the early diagnosis of preterm birth.

3.4 million infants born preterm (before 37 weeks of gestation are completed) in 2020.

900,000 deaths linked to preterm birth in 2019, the leading cause of death in children under five.

4% to 16% preterm births by 2020, depending on the country.

An adaptive evolution of Gardnerella

But how can we explain this peak in Gardnerella nucleotide diversity? Compared to other bacteria, Gardnerella shows a 1.5-fold higher growth rate at the start of pregnancy, more frequent (sidenote: Genetic recombination exchange of genetic information (DNA or RNA fragments in the case of certain viruses) to create new genetic combinations and thus new genomes, ensuring genetic admixture and the maintenance of a diversity that enables adaptation to any change in the environment. ) and greater selection of mutations that benefit this bacterium (and increased elimination of deleterious mutations).
Antibiotics and other xenobiotics are thought to be involved. In fact, the more diversified gene pool of G. swidsinskii seems to correspond to an adaptation to drugs, confirming a previously suggested effect of xenobiotics in the vaginal environment; (sidenote: increased presence of phage-borne antibiotic resistance genes. ) .

From vaginal microbiota to the host

Genomic variation in vaginal bacteria is therefore believed to affect the host’s phenotypes (including pregnancy outcomes). However, the authors do not rule out another explanation, even if they consider it unlikely: the associations between microbial genetic diversity and pregnancy outcomes could also result from unmeasured confounding factors (drugs, chemical compounds, etc.) that might act on both variables.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Pediatrics

Antimicrobial resistance: Patient, your behavior is key! Doctor, your role is essential!

In November, Biocodex and the Biocodex Microbiota Institute join for the 4th year the World AMR Awareness Week (WAAW) to improve understanding of antimicrobial resistance. Recognized by the World Health Organization (WHO) as a top influencer of the WAAW campaign, the Biocodex Microbiota Institute, an international hub of knowledge dedicated to microbiota, takes part in this initiative with exclusive contents for physicians and the lay public. From live savers to microbiota disrupters, the Biocodex Microbiota Institute explores the Janus face of antibiotics.

According to the International Microbiota Observatory, more than 9 out of 10 (95%) people who repeatedly benefited from information from their healthcare professional had adopted specific behaviors to maintain a balanced microbiota. What about antibiotics? Well, according to the same study, only 1 in 3 patients said their healthcare professional had informed them that taking antibiotics could upset their microbiota balance. Because information provided by healthcare professionals is a game-changing vector of behavior, during the WAAW 2024 (18-24th November), the Biocodex Microbiota Institute sheds the light on the key role played by physician regarding information about the impact of antibiotics on microbiota and health.

Train the physicians: pass it on to their patients.

Engaging healthcare professionals (antibiotics prescribers) with tailor-made content.  During the WAAW campaign, Biocodex Microbiota Institute federates its physicians ‘community with two “hub” pages gathering all physicians’ tools (thematic folder, accredited training on dysbiosis and the impact of antibiotics, infographics to share with their patients, news, experts ‘interviews…).
 

Raising awareness of the impact of antibiotics on microbiota remains important. This two “hub” pages aim to provide physicians quick and ready-to-use material to improve their patients understanding of the importance of using antibiotics prudently.

Educate the lay public:  you can take action!


Hailed as one of the greatest medical advances of the 20th century, antibiotics have saved millions of lives. Today, they pose serious public health challenges: their excessive and inappropriate use leads to the emergence of numerous resistances, which, in the long term, could eventually make them ineffective. Moreover, they also can damage the microbiota by inducing a dysbiosis. For the lay public, the Institute investigates this ambivalence role with one “hub” page gathering all content on the impact of antibiotics on microbiota. 
 

From subsidiaries to the Biocodex Microbiota Institute passing through Beauvais manufacturing site, all Biocodex’s collaborators get involved!


For the WAAW campaign 2023, Biocodex Microbiota Institute website homepage, X, Facebook and LinkedIn accounts have turned blue. The Institute’s social networks are not the only ones… the Biocodex 9-hectare manufacturing and logistics center in Beauvais, near Paris, joined the color campaign by wearing blue during WAAW event. More than 30 spotlights have been placed to offer visitors and Biocodex collaborators a blue scenography. From November 18 to 24, the Institute invites Biocodex’s collaborators all over the world to join the campaign on social media thanks to a blue stamp they can put on LinkedIn.

#GoBlueForAMR.
 

Quote Murielle Escalmel

"Antimicrobial resistance is a global public health problem that can reshape the world of tomorrow. That's why we must come together and take action. The Biocodex Microbiota Institute's commitment is to shed light on the impact of antimicrobials on microbiota and stress the vital importance of their appropriate use."

Murielle Escalmel, Scientific Communication Director at the Biocodex Microbiota Institute

What is WAAW?

In 2023, the Quadripartite organizations (FAO, UNEP, WHO and WOAH) has renamed World Antimicrobial Awareness Week to World AMR Awareness Week (WAAW). The WAAW campaign aims to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices for using antimicrobials responsibly among the lay public, health workers and policy makers, to avoid the further emergence and spread of drug-resistant infections.

About the Biocodex Microbiota Institute

The Biocodex Microbiota Institute is an international hub of knowledge that aims to foster better health by spreading information about human microbiota. To do so, the Institute addresses both healthcare professionals and the general public to raise awareness about the central role of this little-known organ.

Biocodex Microbiota Institute press contact

Olivier Valcke,
Public Relations and Head of Publications
+33 6 43 61 32 58
o.valcke@biocodex.com

BMI 23.49
Summary
Off
Sidebar
Off
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Press room

Antimicrobial resistance: Doctor, your role is essential! Patient, your behavior is key!

In November, Biocodex and the Biocodex Microbiota Institute join for the 4th year the World AMR Awareness Week (WAAW) to improve understanding of antimicrobial resistance. Recognized by the World Health Organization (WHO) as a top influencer of the WAAW campaign, the Biocodex Microbiota Institute, an international hub of knowledge dedicated to microbiota, takes part in this initiative with exclusive contents for physicians and the lay public. From live savers to microbiota disrupters, the Biocodex Microbiota Institute explores the Janus face of antibiotics.

According to the International Microbiota Observatory, more than 9 out of 10 (95%) people who repeatedly benefited from information from their healthcare professional had adopted specific behaviors to maintain a balanced microbiota. What about antibiotics? Well, according to the same study, only 1 in 3 patients said their healthcare professional had informed them that taking antibiotics could upset their microbiota balance. Because information provided by healthcare professionals is a game-changing vector of behavior, during the WAAW 2024 (18-24th November), the Biocodex Microbiota Institute sheds the light on the key role played by physician regarding information about the impact of antibiotics on microbiota and health.

Train the physicians: pass it on to their patients.

Engaging healthcare professionals (antibiotics prescribers) with tailor-made content.  During the WAAW campaign, Biocodex Microbiota Institute federates its physicians ‘community with two “hub” pages gathering all physicians’ tools (thematic folder, accredited training on dysbiosis and the impact of antibiotics, infographics to share with their patients, news, experts ‘interviews…).
 

Raising awareness of the impact of antibiotics on microbiota remains important. This two “hub” pages aim to provide physicians quick and ready-to-use material to improve their patients understanding of the importance of using antibiotics prudently.

Educate the lay public:  you can take action!


Hailed as one of the greatest medical advances of the 20th century, antibiotics have saved millions of lives. Today, they pose serious public health challenges: their excessive and inappropriate use leads to the emergence of numerous resistances, which, in the long term, could eventually make them ineffective. Moreover, they also can damage the microbiota by inducing a dysbiosis. For the lay public, the Institute investigates this ambivalence role with one “hub” page gathering all content on the impact of antibiotics on microbiota. 
 

From subsidiaries to the Biocodex Microbiota Institute passing through Beauvais manufacturing site, all Biocodex’s collaborators get involved!


For the WAAW campaign 2023, Biocodex Microbiota Institute website homepage, X, Facebook and LinkedIn accounts have turned blue. The Institute’s social networks are not the only ones… the Biocodex 9-hectare manufacturing and logistics center in Beauvais, near Paris, joined the color campaign by wearing blue during WAAW event. More than 30 spotlights have been placed to offer visitors and Biocodex collaborators a blue scenography. From November 18 to 24, the Institute invites Biocodex’s collaborators all over the world to join the campaign on social media thanks to a blue stamp they can put on LinkedIn.

#GoBlueForAMR.
 

Quote Murielle Escalmel

"Antimicrobial resistance is a global public health problem that can reshape the world of tomorrow. That's why we must come together and take action. The Biocodex Microbiota Institute's commitment is to shed light on the impact of antimicrobials on microbiota and stress the vital importance of their appropriate use."

Murielle Escalmel, Scientific Communication Director at the Biocodex Microbiota Institute

What is WAAW?

In 2023, the Quadripartite organizations (FAO, UNEP, WHO and WOAH) has renamed World Antimicrobial Awareness Week to World AMR Awareness Week (WAAW). The WAAW campaign aims to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices for using antimicrobials responsibly among the lay public, health workers and policy makers, to avoid the further emergence and spread of drug-resistant infections.

About the Biocodex Microbiota Institute

The Biocodex Microbiota Institute is an international hub of knowledge that aims to foster better health by spreading information about human microbiota. To do so, the Institute addresses both healthcare professionals and the general public to raise awareness about the central role of this little-known organ.

More information here

 

Biocodex Microbiota Institute press contact

Olivier Valcke, Public Relations and Head of Publications

+33 6 43 61 32 58

→ o.valcke@biocodex.com

Summary
Off
Sidebar
Off
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Press room

Is vaginal microbiota transfer the new miracle for C-section babies?

The microbiota of cesarean-born infants differs from vaginally delivered infants and is associated with increased disease risks. New research shows that Vaginal microbiota transfer (VMT) to newborns may reverse C-section-related microbiota disturbances. But is VMT safe and effective? Let’s find out.

30% 1 in 3 women are aware that delivery (vaginally or cesarean section) has an impact on the newborn’s gut microbiota

Cesarean section (C-section) is a common mode of delivery worldwide. The global C-section rate remains at 21%, varying widely from 0.6% to 58.1% across regions. However, C-section delivery has been associated with an increased risk of adverse health outcomes, including autoimmune and metabolic disorders, altered gut microbiota and even neurodevelopmental disorders in infants 1. Emerging research points to Vaginal Microbiota Transfer (VMT) as a prospective intervention to ameliorate the gut microbiota maturation and neurodevelopment in C-section babies. However, we are still debating on its safety and effectiveness.

How does VMT work? 

Two hours before the C-section, a wet gauze with sterile saline is placed in the lower vagina of women having a C-section. This gauze remains in situ for roughly an hour, and it’s removed 30 minutes before the administration of prophylactic antibiotics in preparation for the C-section delivery.

Immediately following birth, a trained nurse puts the vaginal gauze in contact with the newborn. The gauze is passed on their lips, face, chest, arms, legs, genitals, and bottom. Then, the nurse wipes their back. It takes about 15 seconds. The babies don't get a bath for 12 hours 2.

What about VMT’s safety and effectiveness? 

A new research published in Cell Host & Microbes conducted a triple-blind randomized controlled trial to assess the safety and efficacy of VMT in improving neurodevelopment, gut microbiota, and metabolome of C-section babies 2. The study enrolled 76 pregnant women that were scheduled for C-sections.

The newborns were randomly assigned to the VMT (n = 35) or control (n = 41) group. The neurodevelopment of the newborns was assessed with the Ages and Stages Questionnaire (ASQ-3) at 6 months of age, their gut microbiota and metabolomes were also analyzed. An additional 33 pregnant women planned for vaginal delivery were also included for comparison. 

Four key findings can be highlighted here:

  • Safety: The study found that VMT is likely safe, with no serious adverse events (SAEs) occurring during the first 42 days after birth.
  • Neurodevelopmental Benefits: Infants who received VMT showed significantly higher neurodevelopment scores at 6 months compared to those in the control.
  • Gut Microbiota Maturation: VMT also led to accelerated maturation of the gut microbiota in cesarean-born infants. The intervention partially normalized the composition of the gut microbiota, looking like that of vaginally delivered infants.
  • Metabolic Function: VMT increased the levels of key fecal metabolites and metabolic functions, including carbohydrate, energy, and amino acid metabolisms, within 42 days after birth.

In contrast to FMT (fecal microbiota transplantation), which is not advisable for DIY attempts and carries substantial risks, VMT stands out as a less perilous medical procedure that can be readily taught to delivery nurses and midwives. Healthcare professionals should consider VMT as a potential intervention to improve the gut microbiome and neurodevelopment of cesarean-born infants.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Obstetrics Off

Like to tan? Mind your skin microbiota!

Exposure to the sun’s rays may cause an imbalance in the microbial community living on the surface of the skin, with those who like to tan apparently most at risk

The skin microbiota The gut microbiota Acne and microbiota Allergic eczema Psoriasis and microbiota Type 2 diabetes Probiotics

Do you feel more beautiful, healthier, and attractive when tanned? Unfortunately, your skin microbiota does not agree... And neither does your health!

So concludes a study 1 on a group of 4 men and 17 women from Northern Europe who spent at least a week on vacation basking in the sun.

The day before their departure, the researchers took a skin sample from the most tanned part of the participants’ forearms in order to analyze the composition of their skin microbiota. They repeated this the day after the participants’ return (D1), 28 days later (D28), and then after 84 days (D84). 

To determine their phototype and changes in their tans, the scientists also measured the color of the skin on their “posteriors” (low exposure to sun) and forearms, both before and after sun exposure.

Warning:

Excessive exposure to the sun can lead to a number of health problems, including skin cancer. However, good sun protection practices can help you reduce the risks. Contact your doctor or pharmacist for advice.

To each their own sun exposure...

The results?

Firstly, it was possible to classify the volunteers into three groups:

  • The “tanning enthusiasts”, who spent a lot of time in the sun during their vacations;
  • The “already tanned”, who had tanned skin before departure and kept it that way;
  • The “wary”, who were minimally tanned before leaving and managed to protect themselves from the sun.

The researchers went on to report that in all the volunteers, three major bacterial phyla – Actinobacteria, Proteobacteria, and Firmicutes – accounted for 95% of all microorganisms.

However, on D1, just after returning from vacation, the “tanning enthusiasts” and the “already tanned” showed a skin microbiota depleted in Proteobacteria. 

While this reduction in diversity disappeared over time, and was non-existent by D28, the finding is important.

Skin microbiota also influenced by gut microbiota

Acne, atopic dermatitis, psoriasis, rosacea... many skin diseases are linked to an imbalance ( (sidenote: Dysbiosis Generally defined as an alteration in the composition and function of the microbiota caused by a combination of environmental and individual-specific factors. Levy M, Kolodziejczyk AA, Thaiss CA, et al. Dysbiosis and the immune system. Nat Rev Immunol. 2017;17(4):219-232.   ) ) not only in the skin microbiota, but also in the gut microbiota. In fact, there is constant communication between the skin and these two microbial communities. This is the famed gut-skin axis 2. But what are the mediators?

Studies have shown that certain metabolites produced by the gut microbiota, known as short-chain fatty acids ( (sidenote: Short chain fatty acids (SCFA) Short chain fatty acids (SCFA) are a source of energy (fuel) for an individual’s cells. They interact with the immune system and are involved in communication between the intestine and the brain. Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Front Endocrinol (Lausanne). 2020;11:25. ) ), are capable of diffusing into the body and acting on the skin 3. Acetate and propionate, for example, are thought to have an anti-inflammatory effect, while propionic acid is thought to act against certain staphylococci responsible for skin infections.

Potentially harmful changes in skin microbiota

Changes in the Proteobacteria content of the skin microbiota have already been observed in people suffering from psoriasis, eczema, and ​​diabetic foot ulcers.

Studies have also shown that a higher skin density of Proteobacteria is associated with better protection against allergy-related skin inflammation. 

These data therefore suggest that a Proteobacteria imbalance in the skin of those who tend to expose themselves to a lot of sun may lead to a deterioration in health.

Proteobacteria: harmful or beneficial?

Proteobacteria do not always get good press. You may have heard of Escherichia coli or Salmonella, which are responsible for infections. Like all bacterial groups, Proteobacteria include some beneficial bacteria, others that are more harmful, and some opportunistic bacteria that help the microbiota when it is healthy, but become harmful when the microbiota presents a dysbiosis 4. For example, Roseomonas mucosa, a skin bacterium belonging to the Proteobacteria group, is known to fight certain skin pathogens 4,5. It’s all about balance!

Admittedly, this study has a number of limitations (small number of volunteers, women overrepresented, only indirect measurement of sun exposure, etc.) and its findings need to be confirmed by larger-scale studies. 

However, it does open up the possibility of one day using products based on certain beneficial bacteria (probiotics) to limit the deterioration of the skin microbiota during sun exposure.

Disclaimer:

High doses of ultraviolet radiation (UVR) are associated with acute and chronic reductions in skin health. Chronic exposure to UVR is the most preventable risk factor for skin cancer. Health care providers recommend sunprotection practices to reduce risk. 

Probiotics

Learn more
Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News

Immunotherapy coupled with FMT in patients with refractory melanoma: a Phase I trial

According to a phase I trial on 20 patients, anti-PD-1 immunotherapy coupled with fecal microbiota transplantation (FMT) induces no more adverse effects than immunotherapy alone, with responses potentially improved.

Over the past decade, the therapeutic arsenal available to treat advanced melanoma has grown. Despite this, half of patients receive no benefit from anti-PD-1 immunotherapy. Combination therapy using (sidenote: Anti-PD-1 immunotherapy based on immune checkpoint inhibitors that target the PD-1 checkpoint, reversing the deactivation by the tumor of the recognition system associated with the PD-1 protein present on the surface of T lymphocytes. The immune system’s effectiveness against tumor cells is thus restored. ) and (sidenote: Anti-CTLA-4 immune checkpoint inhibitor that targets the CTLA-4 checkpoint ) improves response rates, but is associated with immune-related adverse events (irAEs). The gut microbiota regulates the immune system. So what about combining anti-PD-1 with fecal microbiota transplantation (FMT)? This option was explored in a multicenter phase I trial involving (sidenote: aged 48 to 90 (average age of 75.5 years), including 12 men (60%) ) with unresectable or metastatic melanoma who had not previously received anti-PD-1 treatment. They received oral FMT (capsules) from a (sidenote: three healthy male donors (average age of 35 years) provided the feces used for 4, 7, and 9 patients, respectively ) , followed seven days later by a first cycle of (sidenote: nivolumab or pembrolizumab ) .

Comparable safety

The trial’s primary endpoint was safety. FMT induced at most grade 1 or 2 adverse events (diarrhea, flatulence, etc.) in 8 patients (40%). Following anti-PD-1, 17 patients (85%) showed side effects, including 5 patients (25%) with grade 3 irAEs (2 arthritis, 1 fatigue, 1 pneumonia, 1 nephritis) which required temporary discontinuation of treatment. Compared with anti-PD-1 alone (79.5%-93.2% irAEs in phase III clinical trials, including 13.3%-34.0% grade 3-5 irAEs), combined treatment with FMT and anti-PD-1 did not increase the incidence of these events.

Potentially improved response

In terms of efficacy, the objective response rate of 65% (13 patients) was satisfactory and higher than that of anti-PD-1 alone (54%-63% in randomized phase III trials), although the small sample size and absence of a control group (anti-PD-1 only) limit interpretation of the results. The respective donor had no apparent effect on the outcome.

Long-term changes in gut microbiota

(sidenote: at baseline, immediately before anti-PD-1, then 1 month and 3 months after anti-PD-1 ) shows that the diversity of recipients’ gut microbiota only increases after FMT. In terms of composition, one week after FMT, the microbiota of all recipients more closely resembled those of their respective donors. However, this similarity subsequently regressed in future non-responders but increased in responders. 

One month after FMT, the flora of responders was enriched in (sidenote: Ruminococcus, Eubacterium ramuleus, and Faecalibacterium ) and depleted in (sidenote: Clostridium methylpentosum, Enterocloster aldensis, Erysipelatoclostridium ramosum, and Enterocloster clostridioformis ) .

An effect on T lymphocytes?

The study also showed changes in patients’ plasma metabolites, with an increase in primary and secondary bile acids. After FMT, certain T lymphocytes (ICOS+CD8+) increased in the peripheral blood of responders only.

Lastly, mouse models treated with antibiotics prior to FMT confirm the role of FMT in increasing anti-PD-1 efficacy.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Oncology Gastroenterology

Does an unbalanced microbiota at age one lead to allergies at age five?

Delayed maturation of the gut microbiota in early childhood appears to be a universal sign of subsequent allergy development. Could the metabolites involved serve as markers for these allergies or even help prevent them?

Microbiote déséquilibré à 1 an, allergie à 5 ans ?

Asthma, allergic rhinitis, food allergies, and atopic dermatitis are often studied on their own, despite having many similar mechanisms (inflammatory responses, immunoglobulin E). Could something else they have in common be the gut microbiota, which matures in parallel with the infant immune system? To find out, data from 1,115 children included in the vast (sidenote: https://childstudy.ca/ ) longitudinal study were used: 592 children diagnosed with one or more allergic disorders after the age of 5, and 523 children with no signs of allergic sensitization. Regression analysis revealed several risk factors, such as male gender, paternal or maternal history, and antibiotic use before the age of one. Breastfeeding up to six months of age and Caucasian ethnicity appear to be protective.

Less mature gut microbiota

An analysis of stool samples collected at three months and one year of age revealed a delay in microbiota diversification in the children who subsequently developed allergies. Whereas control children had age-appropriate gut flora at age one, future allergic children showed a delay in the maturation of their microbiota. Less maturation of the microbiota at age one seems to be associated with an increased risk of allergic disorders at age five, regardless of the allergy.

Gut microbiota dysbiosis

A gut dysbiosis at age one also characterizes future allergic children: depleted levels of four bacterial species that produce short-chain fatty acids (butyrate-producing Anaerostipes hadrus, Fusicatenibacter saccharivorans and Eubacterium hallii, and acetate-producing Blautia wexlerae) and an increased abundance of five bacteria generally considered pathogenic (Eggerthella lenta, Escherichia coli, Enterococcus faecalis, Clostridium innocuum, and Tyzzerella nexilis). Enrichment in C. innocuum and T. nexilis is correlated with antibiotic use; the abundance of C. innocuum, E. lenta, E. faecalis, and T. nexilis depends on whether or not the baby is breast-fed at six months; while the abundance of C. innocuum and E. lenta is correlated with paternal atopy, and so on.

Metabolites to predict or prevent?

In parallel, the researchers identified 11 metabolic pathways significantly altered in at least two of the allergy diagnoses: nine deleterious pathways correlated mainly with E. coli, while two protective pathways were linked to the bacteria B. wexlerae, F. saccharivorans, A. hadrus, and E. hallii.
A metabolite analysis led to associations with age predicted by the gut microbiota: elevated trace amines (phenylethylamine, tryptamine, and tyramine) promoted inflammation and reduced butyrate production. Thus, the association between altered microbiota maturation and allergies at age five appears to be mediated by these metabolites, which may represent first-choice targets for predicting and/or preventing the development of pediatric allergies.

Microbiota, a diplomatic immunity?

Learn more
Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Pediatrics Pulmonology Gastroenterology

Microbiota imbalance at age one predicts allergies at age five

Canadian researchers 1 are using the stools of one-year-olds to identify microbial communities that can predict subsequent allergies. Their aim is to one day change the course of things via the gut microbiota.

The skin microbiota The ENT microbiota Asthma and microbiota Allergic rhinitis Food allergies

On their fifth birthday, some of the thousands of Canadian children participating in the vast (sidenote: https://childstudy.ca/ ) study, which has followed these children since birth, were diagnosed with allergies such as:

Since their medical records and stool samples collected at three months and one year were carefully preserved as part of the study, the researchers were able to investigate whether there were any warning signs. As it turns out, there appears to be one warning sign universal to all four allergies: the gut microbiota.

Delayed diversity and dysbiosis

Asthma, eczema, food allergies, and hay fever – whatever the allergy –, all future allergy sufferers had a gut microbiota that was insufficiently diversified at age one, as if they were much younger than their birth certs suggested. In addition to this lack of maturity, the microbiota of the future allergy sufferers presented a dysbiosis: four beneficial bacterial species were depleted, while five species generally considered pathogenic were present in excess.

Suspected mechanisms

This early imbalance may explain the lower production of beneficial (sidenote: Short chain fatty acids (SCFA) Short chain fatty acids (SCFA) are a source of energy (fuel) for an individual’s cells. They interact with the immune system and are involved in communication between the intestine and the brain. Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Front Endocrinol (Lausanne). 2020;11:25. ) and the overproduction of inflammatory molecules. In turn, this leads to the subsequent development of allergies... but also gives hope of one day reversing these allergies by correcting gut dysbiosis. 

"Developing therapies that change these interactions during infancy may therefore prevent the development of all sorts of allergic diseases in childhood, which often last a lifetime." 2

Dr Turvey, co-director of CHILD and co-author of the study

Not everyone is equal when it comes to allergies

In the meantime, bear in mind another result of the study: when it comes to allergies, our children are not all equal. Boys are more affected, as are children whose fathers and/or mothers suffer from allergies, and those who were prescribed antibiotics before age one. Conversely, breastfeeding up to six months protects against allergies, as does Caucasian ethnicity. While screening the origin or health record of any future spouse may be out of the question, breastfeeding should be encouraged and antibiotics used with the utmost care and only on prescription.

Antibiotics: what impact on the microbiota and on our health?

Learn more
Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News

The Institute's Team

Biocodex Microbiota Institute: who are we ?

200+ professionals

More than 230 researchers and healthcare professionals across diverse disciplines have been collaborating with the Biocodex Microbiota Institute since its creation in 2017. All together, we join forces and skills to advance microbiota research (gut microbiota but also vaginal, skin, lung…) and raise awareness about its crucial role.

At Biocodex headquarters, the Institute is a team of 7 professionals in science, communications, digital, social networks, etc. with complementary profiles, all experts in their fields. Discover them!

Biographies of the Biocodex Microbiota Institute's team

Olivier Director photo

Olivier Valcke

Biocodex Microbiota Institute’s Director

A former journalist, Olivier has been working in the healthcare sector for nearly 20 years, guided by a deeply held conviction: scientific knowledge only has value if it is widely shared and properly understood.

He strives to put this principle into practice every day by positioning the Institute at the heart of major health challenges: nutrition, antimicrobial resistance and the growing prevalence of chronic diseases.

As Director of the Institute since 2024, Olivier drives this initiative internationally, bringing together experts, healthcare professionals, medical societies and patient associations around a dual ambition: to raise public awareness of the importance of microbiota and to equip healthcare professionals with the tools they need to better integrate microbiota into their medical practice.

Since 2023, he has been leading the International Microbiota Observatory, a large-scale survey conducted among 7,500 people across 11 countries, exploring public knowledge, perceptions and behaviours regarding their microbiota. The findings highlight a major challenge: bridging the gap between what we know (about microbiota) and what we do (to stay healthy).

Turning knowledge into action is therefore the mission for the years ahead!

“Putting the microbiota back at the heart of our health, to make humankind a species on the rise.”

Follow Olivier on Linkedin

Naouel image

Naouel Ait Meddour

Global Social Media Manager

Naouel’s specialty is finding solutions. Always optimistic and never short of ideas, she lives by the motto: “I never lose. I either win or learn.”

After exploring different professional worlds, from finance to real estate, she found her calling in healthcare and communications. Today, as Social Media Manager, she develops and leads the Institute’s social media strategy to make microbiota science accessible, raise its profile and build communities around the world.

A fun fact: she has been there since the Institute was founded! On the front lines for nearly 10 years, she has witnessed microbiota research advance at an incredible pace and watched the subject gradually move out of the shadows and into the spotlight. It’s a journey she continues to tell and share, post after post… and sometimes even trend after trend.

For her, getting to know your microbiota better is already a step towards better health.

Follow Naouel on Linkedin

Mathilde photo

 

Mathilde Baissac

International Digital Manager

Mathilde loves understanding what works… and how to make it work even better. Positive, organised and analytical, she keeps a quote close to her heart that reflects her outlook on life: “Turn towards the sun, and the shadows will fall behind you.”

After completing a preparatory programme and business school, she began her career in marketing in São Paulo, Brazil. In 2020, she joined the Biocodex Microbiota Institute to launch version 2.0 of its website, drawn to its mission of providing accessible, non-promotional scientific information on health and the microbiota.

Today, she develops the website’s acquisition strategies and optimises content to help it reach the widest possible audience. She also relies on data to better understand user behaviour, measure performance and contribute to the Institute’s strategic management.

Outside the digital world, Mathilde is passionate about singing and musical theatre. What fascinates her about the microbiota is its resilience: for her, better understanding and protecting your microbiota means holding one of the keys to good health.

Follow Mathilde on Linkedin

Emilie Photo

 

Émilie Fargier

Scientific and Medical Communication Manager

With a deep-rooted passion for science and over 17 years of experience, Emilie holds a PhD in microbiology. Her journey has transitioned from academic research to industrial research within the pharmaceutical industry. Outside of her scientific endeavors, Emilie is an avid yoga practitioner and has a fervent passion for science fiction and fantasy literature.

As the team's microbiome science explorer, she ensures the scientific veracity of the Biocodex Microbiota Institute's content. Known for her curiosity and ability to demystify complex scientific concepts, her motto, "Unlocking the microbial mysteries for global well-being," reflects her dedication to enhancing health through the power of the microbiota.

Follow Émilie on Linkedin

Floriane photo

 

Floriane Pereira

Scientific and Medical Communication Manager

A scientist by training and curious by nature, Floriane loves exploring, understanding and taking on new challenges. With a PhD in biology, she spent several years conducting academic research in oncology, cell biology and genetics.

At the Biocodex Microbiota Institute, she explores another facet of science: scientific knowledge sharing. She explains the latest advances in microbiota research and ensures the accuracy and reliability of the information published by the Institute, serving as its scientific guarantor.

Enthusiastic and committed, Floriane believes that understanding our microbiota better also means learning how to take better care of our health. This conviction resonates particularly with her own experience of living with endometriosis and fuels her interest in the complex relationships between microbiota, health and well-being.

Outside science, she nurtures her curiosity and finds balance through reading, yoga, dance and sound therapy, a discipline in which she is qualified and which allows her to explore another dimension of well-being through sounds and vibrations. Two worlds that may seem far apart, yet are brought together by a shared desire to explore living systems, the body and the balance within them.

Follow Floriane on Linkedin

Lucile photo

 

Lucile Guieu

Coordinator of the Global Microbiota Scientific Communication Team

Curious by nature, Lucile enjoys researching, understanding and finding solutions, with a particular fondness for varied tasks and days that are never quite the same.

After a career path combining project coordination and international environments, she turned to freelance translation, specialising in public health.

At the Biocodex Microbiota Institute, Lucile coordinates the writing, translation and publication of website news articles. She also oversees budget monitoring and manages the publications library. Her guiding principle? Keeping things running smoothly and making everyday work easier for the team.

For her, the symbiosis between our bodies and their microbiota is a model to follow and continue exploring.

Follow Lucile on Linkedin

Alexandra Jean Photo

 

Alexandra Jean

Digital Marketing Apprentice

Having built her academic and professional background entirely in the digital field, Alexandra is continuing along the same path to further develop her expertise.

As a digital marketing apprentice at the Biocodex Microbiota Institute, she helps promote knowledge about the microbiota through a wide range of responsibilities: managing and updating website content, SEO optimisation, creating social media content, producing visuals and videos, and coordinating digital communication projects.

Joining the Biocodex Microbiota Institute allows her to put her skills to work in sharing reliable and accessible scientific information, while helping raise awareness of the importance of the microbiota for health.

Follow Alexandra on Linkedin

Kawthar Mekouar Photo

 

Kawthar Mekouar

Digital Marketing Apprentice

Kawthar specialised in web development and interactive media before continuing her studies with a Master’s degree in Management, Service Innovation and Digital Technology. Her experience has enabled her to develop skills in development, digital creation, communications and project management.

What inspires her beyond the digital world? Passionate about figure skating, she is also interested in sports and the arts in all their forms. She also enjoys taking the time to care for plants and flowers, and getting lost in a good book.

At the Biocodex Microbiota Institute, she contributes to the management of digital projects and website content. She particularly appreciates the Institute’s scientific focus and the opportunities digital technology offers to make scientific knowledge accessible to as many people as possible.

Joining the Institute therefore allows her to put her digital skills to work in sharing knowledge about the microbiota.

Follow Kawthar on Linkedin

About us

Go back to the "About us" page
BMI 24.04
Summary
Off
Sidebar
Off
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Article Off